A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is a novel human coronavirus strain (HCoV) was initially reported in December 2019 in Wuhan City, China. This acute infection caused pneumonia-like symptoms and other respiratory tract illness. Its higher transmission and infecti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nithishwer Mouroug Anand, Devang Haresh Liya, Arpit Kumar Pradhan, Nitish Tayal, Abhinav Bansal, Sainitin Donakonda, Ashwin Kumar Jainarayanan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bf0a70d8aec74fd0b85be980515e1949
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf0a70d8aec74fd0b85be980515e1949
record_format	dspace
spelling	oai:doaj.org-article:bf0a70d8aec74fd0b85be980515e19492021-12-02T20:18:56ZA comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.1932-620310.1371/journal.pone.0248553https://doaj.org/article/bf0a70d8aec74fd0b85be980515e19492021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0248553https://doaj.org/toc/1932-6203The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is a novel human coronavirus strain (HCoV) was initially reported in December 2019 in Wuhan City, China. This acute infection caused pneumonia-like symptoms and other respiratory tract illness. Its higher transmission and infection rate has successfully enabled it to have a global spread over a matter of small time. One of the major concerns involving the SARS-COV-2 is the mutation rate, which enhances the virus evolution and genome variability, thereby making the design of therapeutics difficult. In this study, we identified the most common haplotypes from the haplotype network. The conserved genes and population level variants were analysed. Non-Structural Protein 10 (NSP10), Nucleoprotein, Papain-like protease (Plpro or NSP3) and 3-Chymotrypsin like protease (3CLpro or NSP5), which were conserved at the highest threshold, were used as drug targets for molecular dynamics simulations. Darifenacin, Nebivolol, Bictegravir, Alvimopan and Irbesartan are among the potential drugs, which are suggested for further pre-clinical and clinical trials. This particular study provides a comprehensive targeting of the conserved genes. We also identified the mutation frequencies across the viral genome.Nithishwer Mouroug AnandDevang Haresh LiyaArpit Kumar PradhanNitish TayalAbhinav BansalSainitin DonakondaAshwin Kumar JainarayananPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 3, p e0248553 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nithishwer Mouroug Anand Devang Haresh Liya Arpit Kumar Pradhan Nitish Tayal Abhinav Bansal Sainitin Donakonda Ashwin Kumar Jainarayanan A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
description	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is a novel human coronavirus strain (HCoV) was initially reported in December 2019 in Wuhan City, China. This acute infection caused pneumonia-like symptoms and other respiratory tract illness. Its higher transmission and infection rate has successfully enabled it to have a global spread over a matter of small time. One of the major concerns involving the SARS-COV-2 is the mutation rate, which enhances the virus evolution and genome variability, thereby making the design of therapeutics difficult. In this study, we identified the most common haplotypes from the haplotype network. The conserved genes and population level variants were analysed. Non-Structural Protein 10 (NSP10), Nucleoprotein, Papain-like protease (Plpro or NSP3) and 3-Chymotrypsin like protease (3CLpro or NSP5), which were conserved at the highest threshold, were used as drug targets for molecular dynamics simulations. Darifenacin, Nebivolol, Bictegravir, Alvimopan and Irbesartan are among the potential drugs, which are suggested for further pre-clinical and clinical trials. This particular study provides a comprehensive targeting of the conserved genes. We also identified the mutation frequencies across the viral genome.
format	article
author	Nithishwer Mouroug Anand Devang Haresh Liya Arpit Kumar Pradhan Nitish Tayal Abhinav Bansal Sainitin Donakonda Ashwin Kumar Jainarayanan
author_facet	Nithishwer Mouroug Anand Devang Haresh Liya Arpit Kumar Pradhan Nitish Tayal Abhinav Bansal Sainitin Donakonda Ashwin Kumar Jainarayanan
author_sort	Nithishwer Mouroug Anand
title	A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
title_short	A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
title_full	A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
title_fullStr	A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
title_full_unstemmed	A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
title_sort	comprehensive sars-cov-2 genomic analysis identifies potential targets for drug repurposing.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/bf0a70d8aec74fd0b85be980515e1949
work_keys_str_mv	AT nithishwermourouganand acomprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT devanghareshliya acomprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT arpitkumarpradhan acomprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT nitishtayal acomprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT abhinavbansal acomprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT sainitindonakonda acomprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT ashwinkumarjainarayanan acomprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT nithishwermourouganand comprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT devanghareshliya comprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT arpitkumarpradhan comprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT nitishtayal comprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT abhinavbansal comprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT sainitindonakonda comprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing AT ashwinkumarjainarayanan comprehensivesarscov2genomicanalysisidentifiespotentialtargetsfordrugrepurposing
_version_	1718374248649588736

A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.

Ejemplares similares